4-AcO-DiPT

3-[2-(Diisopropylamino)ethyl]-1H-indol-4-yl acetate

4-Acetoxy-DiPT, Ipracetin, Iprocetyl, Aces, 4-Ace

Psychoactive Class

Chemical Class

4-AcO-DiPT is a synthetic psychedelic of the tryptamine class, first described by Alexander Shulgin by 2003 and encountered as a novel designer drug in 2005¹. It is thought to act primarily as a prodrug of 4-HO-DiPT.¹ The substance is notable for producing a unique combination of physical euphoria and stimulation alongside atypically minimal visual and introspective psychedelic effects compared to related tryptamines.

Dosage & Duration

Dosage

Threshold~3 mg

Light5-10 mg

Moderate10-20 mg

Strong20-35 mg

Heavy35+ mg

4-AcO-DiPT occurs as both a hydrochloride salt and a freebase. The freebase is roughly 10% more potent by weight than the equivalent mass of the HCl salt.

Duration

Onset15-40 minutes

Come Up20-40 minutes

Peak1.5-2 hours

Offset1-1.5 hours

After Effects2-6 hours

Total3-4 hours

Subjective Effects

Effects vary widely by individual, dose, and context.

Forked from Subjective Effect Documentation work

by Josie KinsAugust 2016.

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

4-AcO-DiPT acts as a serotonin 5-HT2 receptor agonist, likely functioning as a partial agonist at the 5-HT2A receptor specifically.¹ Its psychedelic effects are believed to stem primarily from this 5-HT2A activity, consistent with the head-twitch response it produces in rodents (a behavioral proxy for psychedelic activity).¹ Its direct potency at 5-HT2 receptors is considerably reduced relative to 4-HO-DiPT.¹ Additional serotonin receptors may contribute to its overall effects, though very little pharmacological data currently exists for this substance.

Pharmacokinetics

4-AcO-DiPT is thought to function primarily as a prodrug of 4-HO-DiPT, undergoing deacetylation in the body in a manner analogous to the conversion of psilocybin to psilocin.¹ This prodrug relationship has not yet been confirmed through formal pharmacokinetic studies¹, and very little data exists regarding the metabolism or pharmacokinetic properties of this substance.

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

Lithium

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

Tramadol

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

AmphetaminesCannabisCocaineDiphenhydramine

TripSit

Tolerance

Full Tolerance

Tolerance to the effects develops almost immediately after ingestion.

Baseline Reset

7 days in the absence of further consumption

Half Tolerance

Approximately 3 days

Cross Tolerance

Psychedelics (all psychedelics will have a reduced effect following 4-AcO-DiPT consumption)

Harm Potential

Addiction & Dependence

Psychological

Low

Not generally habit-forming and the desire to use it can decrease with repeated use; however, compulsive redosing is atypically prominent for a psychedelic tryptamine, likely due to its short duration, hedonic effects, and rapid onset/offset profile. May possess higher liability for frequent consumption relative to most psychedelics.

Psychosis Risk

Risk of adverse psychological reactions including psychosis is noted primarily in combination with other substances such as cannabis, lithium, or stimulants; psychosis from the substance alone is not well-documented. As with other psychedelics, risk increases with higher doses.²

Seizure Risk

Described as a likely rare effect that may occur in predisposed individuals, especially under physically taxing conditions such as dehydration, fatigue, or undernourishment. No documented cases of seizures have been reported with this compound alone.

History & Culture

4-AcO-DiPT was first characterized in the scientific literature by Alexander Shulgin, with documentation appearing by 2003. The compound appears in TiHKAL (Tryptamines I Have Known and Loved), Shulgin's comprehensive reference work on tryptamine compounds co-authored with Ann Shulgin.…

Legality

By Country

United StatesUnscheduled

Not scheduled under the Controlled Substances Act. However, due to structural similarities to scheduled tryptamines such as psilocin, possession and sale for human consumption may be prosecuted under the Federal Analogue Act. Pending cases have existed since July 2004 involving vendors selling this substance, though no convictions have established further legal precedent.

FinlandControlled substance

Banned in December 2014 under a government regulation that prohibited over 100 psychoactive chemicals.

JapanDesignated Substance (Shitei-Yakubutsu)

Controlled under the Pharmaceutical Affairs Law, making both possession and sale illegal.

SwitzerlandControlled (Verzeichnis E)

Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.

DenmarkSchedule B

Listed as a Schedule B controlled substance under Danish drug control legislation.

GermanyControlled (NpSG)

Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019.³ Production, import with intent to distribute, administration to others, and trading are punishable offenses.⁴ Possession is illegal but not subject to criminal penalties.

SwedenIllegal

Classified as a health hazard under the Act on the Prohibition of Certain Goods Dangerous to Health (Lagen om förbud mot vissa hälsofarliga varor) as of March 1, 2005, in regulation SFS 2005:26. Both possession and sale are prohibited.

United KingdomClass A

Controlled under the Misuse of Drugs Act 1971.⁵ This classification applies because 4-AcO-DiPT is an ester of 4-HO-DiPT, which is controlled under the tryptamine catch-all clause.⁵

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 4-AcO-DiPT article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

4-AcO-DiPT

3-[2-(Diisopropylamino)ethyl]-1H-indol-4-yl acetate

4-Acetoxy-DiPT, Ipracetin, Iprocetyl, Aces, 4-Ace

Psychoactive Class

Psychedelic Hallucinogen

Chemical Class

Tryptamine